niclosamide novel solution / Bayer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
niclosamide novel solution / Bayer
2020-002233-15: A study to investigate the safety and efficacy of two approved drugs, niclosamide and camostat, administered alone and in combination and compared to placebo in COVID-19 patients

Ongoing
2
72
Europe
Niclosamide, Camostat, Chewable tablet, Film-coated tablet, Yomesan®, Camostat Mesilate Tablets 100mg "Sawai"
Charité Research Organisation GmbH, Bayer AG
SARS-Coronavirus 2 disease 2019 (COVID-19), Coronavirus disease 2019 (COVID-19), Diseases [C] - Virus Diseases [C02]
 
 
NICCAM, NCT04750759: Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Terminated
2
4
Europe
Niclosamide + Camostat, Yomesan, Foipan, Placebo
Charité Research Organisation GmbH, Bayer
Covid19
10/21
10/21

Download Options